BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:MiNK Therapeutics\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies MiNK Therapeutics\, Inc.'s drugs 
 run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07615010-3287@assetmemo.bio
DTSTAMP:20261121T005942Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:agenT-797: Phase 2 readout est. (NCT07615010)
DESCRIPTION:agenT-797\, phase 2.\nStudy: A Clinical Trial to Evaluate agenT
 -797 Plus Standard of Care in Participants With Severe Pneumonia With Mode
 rate to Severe Acute Hypoxemic Respiratory Failure\nEstimated primary comp
 letion: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ag
 ent-797#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07615010
URL:https://assetmemo.bio/drug/agent-797#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
